Moderna’s stock has doubled this week. There are better buys out there now.

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

Spread the loveImagine a future where your cancer treatment isn’t a blunt instrument, but a precision-guided missile, ...

Moderna and Merck scored a big win for their cancer vaccine on Wednesday. But analysts say it's too early to call it a home ...

Moderna just transformed from a cash-burning vaccine maker into a serious acquirer, and four biotech targets are already ...

Moderna (MRNA) surged about 177% after it and Merck (MRK) reported the first positive Phase 3 result for an mRNA cancer ...

The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

Ahead of US stock trading that day, Moderna and Merck jointly announced the results of the Phase III INTerpath-001 clinical ...

Today, Aug. 19, 2026, Moderna's personalized cancer vaccine met its late-stage goal, with the company and Merck planning an ...

Moderna and Merck's mRNA cancer vaccine marks a breakthrough in personalized oncology, with broad financial implications for ...

Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling. Click here for risks and drug portfolio ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rocketing higher Wednesday morning, with the stock up 93% to $121 ...